Sen-Jam Pharmaceutical将其首创的 FDA宿醉预防疗法 SJP-001推进至加拿大二期临床试验-动脉网

Sen-Jam Pharmaceutical Advances First-in-Class FDA Hangover Prevention Therapy, SJP-001, to Phase 2 Trials in Canada

CISION 等信源发布 2025-07-25 20:51



可切换为仅中文







Cliantha Research spearheads clinical study as growing evidence and investor enthusiasm converge around inflammation-based innovation.

Cliantha Research 在越来越多的证据和投资者对基于炎症的创新充满热情的情况下，引领了临床研究。

HUNTINGTON, N.Y.

纽约州亨廷顿

，

July 25, 2025

2025年7月25日

/PRNewswire/ --

Sen-Jam Pharmaceutical

参见Jam制药公司

has initiated a Phase 2 clinical trial for its pioneering hangover prevention therapy,

已为其开创性的宿醉预防疗法启动了第二阶段临床试验，

SJP-001

, now underway in

，现在正在进行中

Canada

加拿大

with global research partner Cliantha. This milestone positions SJP-001 to become

与全球研究合作伙伴Cliantha一起。这一里程碑使SJP-001有望成为

the first FDA therapy to directly target the inflammatory root cause of alcohol-induced symptoms

首个直接针对酒精诱导症状的炎症根本原因的FDA疗法

—moving beyond surface-level relief like hydration. It also represents

——超越了如补水这样的表面缓解。它还代表了

a flagship validation of Sen-Jam's PAIR Technology (Preemptive Anti-Inflammatory Regulators) platform—a scalable, modular technology designed to unlock next-generation broad spectrum anti-inflammatory therapies

Sen-Jam的PAIR技术（抢先抗炎调节剂）平台的旗舰验证——一种可扩展、模块化的技术，旨在解锁下一代广谱抗炎疗法。

for a wide range of inflammation-driven conditions with massive unmet needs.

适用于一系列炎症驱动的、存在大量未满足需求的疾病。

继续阅读

In Development The First Ever Evidence-Based Hangover Solution - Grandma's Remedies Just Got Outsmarted

开发中的首个基于证据的宿醉解决方案——祖母的偏方刚刚被超越了。

Amid increasing global scrutiny of alcohol's long-term health risks, SJP-001 arrives at a pivotal moment

在全球对酒精长期健康风险的审查日益严格之际，SJP-001 应运而生，恰逢其时。

. In

。在

January 2025

2025年1月

, the

，这个

U.S. Surgeon General issued a stark warning

美国卫生局局长发出了严厉警告

linking chronic alcohol consumption to increased cancer risk, citing systemic inflammation as a major driver

将慢性酒精摄入与癌症风险增加联系起来，称系统性炎症是一个主要驱动因素。

—a warning that echoes the scientific foundation of Sen-Jam's therapeutic approach.

——这一警告呼应了森-贾姆治疗法的科学基础。

We're not only addressing the acute discomfort of the morning after,

我们不仅仅是在缓解第二天早上的急性不适，

said

说

Jackie Iversen

杰基·伊弗森

, RPh, MS, Co-Founder and Chief Clinical Officer at Sen-Jam. 'We're contributing to the global response to alcohol-related inflammation and long-term health implications.'

，RPh，MS，Sen-Jam联合创始人兼首席临床官。“我们正在为全球应对酒精相关的炎症和长期健康影响做出贡献。”

'At Desire Ventures, we back companies that combine purpose and performance. Supporting a Canadian-led clinical program with worldwide implications makes Sen-Jam a natural fit,'

“在Desire Ventures，我们支持将目标与绩效相结合的公司。支持一个具有全球影响的加拿大主导的临床项目，使得Sen-Jam成为一个自然的选择。”

said

说

Assad S. Aslam

阿萨德·S·阿斯拉姆

, Managing Partner of

，管理合伙人

Desire Ventures

欲望冒险

, an investor in the program.

，该计划的投资者。

Sen-Jam's peer-reviewed publication from

Sen-Jam的经过同行评审的出版物来自

January 2025

2025年1月

further elaborates on this connection, reinforcing the need for innovation specifically targeting inflammatory responses:

进一步阐述了这一联系，强调了需要特别针对炎症反应进行创新：

Read: Alcohol Use, Inflammation, and Cancer Risk

阅读：酒精使用、炎症与癌症风险

Inflammation is the Mechanism. SJP-001 is the Solution. And the Market is Ripe for a Leader.

炎症是机制。SJP-001 是解决方案。市场已成熟，等待一位领导者。

SJP-001 is protected by

SJP-001 受到保护

23 global patents

23项全球专利

and built on a

并建立在

novel combination of repurposed drugs

新型的重新利用药物组合

designed to safely disrupt the

旨在安全地打破

inflammatory cascade triggered by alcohol consumption

饮酒引发的炎症级联反应

. Unlike surface-level remedies, SJP-001 targets the biological driver of hangover symptoms—offering a scientifically grounded, first-in-class approach.

与表面的补救措施不同，SJP-001 针对宿醉症状的生物学驱动因素——提供了一种科学基础上的、首创的方法。

published pilot study

已发表的试点研究

has already shown

已经展示

significant reductions in both the severity and duration of symptoms

症状的严重程度和持续时间均显著减少

, confirming the compound's early efficacy:

，证实了该化合物的早期疗效：

Pilot Study of SJP-001 – PubMed

SJP-001的初步研究 – PubMed

Further reinforcing this approach,

进一步强化这一方法，

Dr.

博士

Joris Verster

乔里斯·费斯特拉

—widely regarded as the

——被广泛认为是

father of alcohol hangover research

酒精宿醉研究之父

—has recently published a comprehensive review of existing remedies underscoring the importance of inflammation-targeted interventions. His analysis validates anti-inflammatory mechanisms as the most promising route for future therapies:

——最近发表了一篇全面的现有疗法综述，强调了针对炎症干预的重要性。他的分析证实，抗炎机制是未来治疗最有前景的方向：

Verster 2024 Review – Journal of Translational Medicine

Verster 2024 回顾——转化医学杂志

'Our innovation is about more than relief—it's about resilience, well-being, and protecting people who choose to consume alcohol socially,' continued Iversen. 'According to the World Health Organization, that's approximately

“我们的创新不仅仅是关于缓解——它是关于韧性、福祉，以及保护那些选择社交性饮酒的人，”艾弗森继续说道。“根据世界卫生组织的数据，这个数字大约是

2.4 billion people globally

全球24亿人

。

And the global market is finally catching up to science.

全球市场终于赶上了科学的步伐。

Grand View Research

大视野研究

projects the hangover remedies market will grow at a

预计宿醉疗法市场将增长

14.9% CAGR

14.9% 的年复合增长率

, reaching

，到达

$6.2 billion

62亿美元

by 2030

到2030年

—a category long dismissed as folklore now emerging as a credible, clinical frontier.

——一个长期以来被视为民间传说的类别，如今正成为可信的临床前沿。

A Movement in Motion: Sen-Jam's Community-Powered Model Attracts 1,100+ Investors Backing the Future of Preventive Pharma

运动中的力量：Sen-Jam的社区驱动模式吸引了1100多名投资者支持预防性制药的未来

The tides are turning in healthcare. As consumers demand more control over their well-being, and investors seek meaningful exposure to

医疗保健领域的风向正在转变。随着消费者要求对自身健康有更多掌控，投资者寻求有意义的涉足机会，

preventive, protective, and more elegant inflammation-targeted therapies

预防性、保护性和更具针对性的炎症治疗

, Sen-Jam is answering the call—with science, structure, and choice.

，森-贾姆正以科学、结构和选择来响应这一号召。

To give mission-aligned supporters maximum flexibility, Sen-Jam is offering three complementary ways to participate:

为了给与使命一致的支持者最大的灵活性，Sen-Jam 提供了三种互补的参与方式：

Philanthropic Giving via

通过 philanthropic giving 进行捐赠

CataCap

凯塔资本

Community Investing via

通过社区投资

Wefunder

微投网

Reg D 506C - Contact Sen-Jam Directly

Reg D 506C - 直接联系Sen-Jam

'We're democratizing access to a market traditionally closed off to all but the largest players,' said

“我们正在使传统上只对最大参与者开放的市场变得民主化，”

Jim Iversen

吉姆·艾弗森

, CEO. 'This is about more than raising capital. It's about

，首席执行官。‘这不仅仅是筹集资金。而是关于

building a values-aligned community

建立一个价值观一致的社区

that's invested in the future of health and in helping each other live healthier, longer lives.'

致力于健康的未来，并帮助彼此过上更健康、更长寿的生活。

Sen-Jam has already attracted

森贾姆已经吸引了

over 1,100 investors

超过1100名投资者

, with about

，大约有

30% choosing to invest a second time

30%选择再次投资

—a signal of trust, traction, and shared belief in the company's mission and model. If you're interested in exploring their fundraising campaign, visit their

——这是对公司使命和模式的信任、吸引力和共同信念的信号。如果你有兴趣了解他们的筹款活动，请访问他们的

Wefunder

微投网

offer.

提供。

Interested parties are also invited to join Sen-Jam's leadership for an exclusive deep dive into SJP-001's market potential, the science behind it, and how you can participate in the journey. Next

感兴趣的各方也被邀请加入Sen-Jam的领导层，进行一场独家深入探讨SJP-001的市场潜力、其背后的科学原理，以及您如何参与这一旅程。接下来

Wednesday, July 30th

7月30日，星期三

在

1pm EST

下午1点（美国东部时间）

. Registration for this event is required and can be secured

. 参加此活动需要注册，可以通过以下方式确保注册成功

here

这里

。

About Sen-Jam Pharmaceutical

关于森-贾姆制药

Sen-Jam Pharmaceutical is a drug innovation company developing safe and efficacious therapies for some of the world's most widespread and costly health challenges. By repurposing well-characterized small molecules through its proprietary delivery platform—and leveraging the FDA's accelerated 505(b)(2) regulatory pathway—Sen-Jam is building a .

Sen-Jam Pharmaceutical是一家药物创新公司，致力于为世界上一些最普遍且代价高昂的健康挑战开发安全有效的治疗方法。通过利用其专有的递送平台重新定位那些已被充分研究的小分子，并借助FDA加速的505(b)(2)监管途径，Sen-Jam正在构建一个。

new class of anti-inflammatories

新型抗炎药

designed to target the

旨在针对

entire spectrum of inflammatory pathways

炎症通路的整个范围

, not just one or two like traditional blockbusters. This platform approach opens doors to faster clinical validation, broader indications, and therapies that are not only effective—but accessible, safe, and scalable.

，而不仅仅是一两个适应症，如同传统的重磅药物。这个平台方法为更快的临床验证、更广泛的适应症以及不仅有效而且可及、安全且可扩展的疗法打开了大门。

Investor information available at

投资者信息可在以下位置获取

Wefunder

. Learn more at

. 了解更多，请访问

www.sen-jam.com

。

CONTACT INFORMATION:

联系方式：

Sen-Jam Pharmaceutical

参见Sen-Jam Pharmaceutical